Drug Trial Radar · NCT03738423
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jun 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
129
Actual
Start
Nov 13, 2018
Primary completion
Mar 13, 2020
Study completion Jul 24, 2020
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Nov 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to assess the efficacy of REGN3500 monotherapy in Atopic dermatitis (AD), as well as understand the dose-response relationship, compared with placebo treatment, in adult patients with moderate-to-severe AD. Secondary objectives are to: * Assess the safety and tolerability of subcutaneous (SC) doses of REGN3500 monotherapy in adult patients with moderate-to-severe AD * Assess the Pharmacokinetics (PK) of REGN3500 in adult patients with moderate-to-severe AD * Assess the immunogenicity of REGN3500 in adult patients with moderate-to-severe AD
Conditions
- Atopic Dermatitis
Interventions
REGN3500Drug
Administered subcutaneous (SC)
REGN3500-Matching PlaceboDrug
Administered subcutaneous (SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16Time frame: Week 16
- Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16Time frame: Week 16
Locations
89 sites in 11 countries. Site status is shown where the registry gives one.
Regeneron Study Site
Birmingham, Alabama
Regeneron Study Site
Phoenix, Arizona
Regeneron Study Site
Scottsdale, Arizona
Regeneron Study Site
Tucson, Arizona
Regeneron Study Site
Little Rock, Arkansas
Regeneron Study Site
Fountain Valley, California
Regeneron Study Site
Fremont, California
Regeneron Study Site
Oceanside, California
Regeneron Study Site
Sacramento, California
Regeneron Study Site
Santa Monica, California
Regeneron Study Site
Jacksonville, Florida
Regeneron Study Site
Macon, Georgia
Regeneron Study Site
Skokie, Illinois
Regeneron Study Site
Evansville, Indiana
Regeneron Study Site
Overland Park, Kansas
Regeneron Study Site
Louisville, Kentucky
Regeneron Study Site
Louisville, Kentucky
Regeneron Study Site
Louisville, Kentucky
Regeneron Study Site
Saint Joseph, Michigan
Regeneron Study Site
Minneapolis, Minnesota
Regeneron Study Site
Las Vegas, Nevada
Regeneron Study Site
Lebanon, New Hampshire
Regeneron Study Site
New York, New York
Regeneron Study Site
Wilmington, North Carolina
Regeneron Study Site
Cincinnati, Ohio
Regeneron Study Site
Norman, Oklahoma
Regeneron Study Site
North Charleston, South Carolina
Regeneron Study Site
San Antonio, Texas
Regeneron Study Site
San Antonio, Texas
Regeneron Study Site
San Antonio, Texas
Regeneron Study Site
Norfolk, Virginia
Regeneron Study Site
Kogarah, Australia
Regeneron Study Site
Melbourne, Australia
Regeneron Study Site
Calgary, Alberta, Canada
Regeneron Study Site
Hamilton, Ontario, Canada
Regeneron Study Site
Hamilton, Ontario, Canada
Regeneron Study Site
Toronto, Ontario, Canada
Regeneron Study Site
Windsor, Ontario, Canada
Regeneron Study Site
Verdun, Quebec, Canada
Regeneron Study Site
Brno, Czechia
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.